Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study
- PMID: 27879187
- PMCID: PMC5122314
- DOI: 10.1017/S0033291716002099
Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study
Abstract
Background: Concerns relating to increased use of psychotropic medication contrast with those of under-treatment and under-recognition of common mental disorders in children and young people (CYP) across developed countries. Little is known about the indications recorded for antidepressant prescribing in primary care in CYP.
Method: This was an electronic cohort study of routinely collected primary-care data from a population of 1.9 million, Wales, UK. Poisson regression was undertaken to model adjusted counts of recorded depression symptoms, diagnoses and antidepressant prescriptions. Associated indications were explored.
Results: 3 58 383 registered patients aged 6-18 years between 1 January 2003 and 31 December 2013 provided a total of 19 20 338 person-years of follow-up. The adjusted incidence of antidepressant prescribing increased significantly [incidence rate ratio (IRR) for 2013 = 1.28], mainly in older adolescents. The majority of new antidepressant prescriptions were for citalopram. Recorded depression diagnoses showed a steady decline (IRR = 0.72) while depression symptoms (IRR = 2.41) increased. Just over half of new antidepressant prescriptions were associated with depression (diagnosis or symptoms). Other antidepressant prescribing, largely unlicensed, was associated with diagnoses such as anxiety and pain.
Conclusion: Antidepressant prescribing is increasing in CYP while recorded depression diagnoses decline. Unlicensed citalopram prescribing occurs outside current guidelines, despite its known toxicity in overdose. Unlicensed antidepressant prescribing is associated with a wide range of diagnoses, and while accepted practice, is often not supported by safety and efficacy studies. New strategies to implement current guidance for the management of depression in CYP are required.
Keywords: Antidepressants; children; depression; prescribing; young people.
Figures
References
-
- APA (2013). Diagnostic and statistical Manual of Mental Disorders V. American Psychiatric Association (http://www.psychiatry.org/psychiatrists/practice/dsm/dsm-5). Accessed 11 January 2016.
-
- BMA & NHS Employers (2006). Revisions to the GMS Contract 2006/07. Delivering Investment in General Practice. BMA: London.
-
- Committee of Safety of Medicines (2003). Paroxetine (seroxat) – variation assessment report – proposal to contraindicate in adolescents and children under 18 years with major depressive disorder. Report of the Committee on Safety of Medicines Expert Working Group on the safety of selective serotonin reuptake inhibitors, London: The Stationery Office.
-
- Department of Health (2012). Annual Report of the Chief Medical Officer – Our Children Deserve Better, Prevention Pays. Chapter 10, p9 (https://www.gov.uk/government/uploads/system/uploads/attachment_data/fil...). Accessed 25 June 2016.
-
- Department of Health (2015). Report of the Children and Young People's Mental Health Taskforce. Future in Mind: promoting, protecting and improving our children and young people's mental health and well-being. Chapter 1, p13. Chapter 3, p31 (https://www.gov.uk/government/uploads/system/uploads/attachment_data/fil...). Accessed 25 June 2016.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
